407 results match your criteria: "Urticaria Solar"
A case of solar urticaria complicated by eosinophilic granulomatosis with polyangiitis treated with mepolizumab.
J Dermatol
September 2024
Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.
New insights into chronic inducible urticaria.
Curr Allergy Asthma Rep
August 2024
Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, 10178, Berlin, Germany.
Article Synopsis
- Chronic inducible urticaria (CIndU) is a difficult-to-manage condition marked by recurring hives and swelling, triggered by specific factors, and recent research has focused on understanding its causes and improving treatment options.
- New methods for evaluating patient experiences have been developed, highlighting the significant impact CIndU has on quality of life and enabling better diagnosis through provocation tests for different subtypes.
- Currently, second-generation non-sedating antihistamines are the primary recommended treatment, but they often fall short; however, off-label use of omalizumab shows promise, along with other emerging therapies being researched for future options.
A case of solar urticaria with inhibition spectrum in ultraviolet radiation A and visible light successfully treated by ultraviolet radiation A rush hardening therapy.
J Dermatol
July 2024
Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.
Chronic Inducible Urticaria.
Immunol Allergy Clin North Am
August 2024
Department of Dermatology and Venerology, Kepler University Hospital, Urticaria Center of Excellence and Reference (UCARE), Linz, Austria; Center for medical research, Johannes Kepler University, Linz, Austria; Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany. Electronic address:
Article Synopsis
- * Diagnosis relies on patient history, trigger tests, and self-reported symptoms.
- * Current treatments mirror those for chronic spontaneous urticaria but are largely off-label; new targeted therapies are in clinical trials due to the significant impact on patients.
Solar Urticaria and Omalizumab: A Retrospective Case-Control Study and Follow-Up.
Actas Dermosifiliogr
October 2024
Dermatology Department, Hospital General Universitario de Valencia, España.
Successful serial plasmapheresis for solar urticaria, a case report and literature review.
J Dermatolog Treat
December 2024
Photodermatology Unit, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Article Synopsis
- The study highlights the effectiveness of traditional therapeutic plasmapheresis (TPE) as a treatment for difficult cases of solar urticaria (SU) that don't respond to common medications.* -
- A specific case involving a patient who underwent 42 TPE procedures over five years showed significant improvement in their condition, as indicated by increased resistance to UV light during testing after treatment.* -
- The research also compares the outcomes of this case with previous studies on TPE for SU, showing that patients with positive intradermal tests generally benefited more from TPE, although some relapsed in a short time.*
[Solar urticaria and polymorphous light eruption].
Dermatologie (Heidelb)
July 2024
Zentrum für Dermatologie, Allergologie und Dermatochirurgie, Helios Universitätsklinikum Wuppertal, Wuppertal, Deutschland.
Article Synopsis
- Solar urticaria is a rare skin condition triggered by UV radiation or visible light, likely caused by an allergic reaction, leading to severe symptoms that significantly affect patients' quality of life.
- Polymorphous light eruption, in contrast, is a more common condition resulting from a type IV allergic reaction to photoallergens, with skin lesions that heal despite sun exposure and generally less impact on quality of life.
- Both conditions are diagnosed through light provocation and can benefit from a treatment approach called light hardening, highlighting their distinct clinical features and management strategies.
Overexposure to ultraviolet radiation in solar urticaria.
BMJ Case Rep
May 2024
Photobiology Unit, Department of Dermatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK.
A man in his 50s was diagnosed with solar urticaria following monochromated light testing that demonstrated exquisite photosensivity to ultraviolet (UV) A, UV B (UVB) and visible light.Treatment options for this photodermatosis are limited; UVB phototherapy is one modality that can be appropriate in some patients. This is administered at very low doses in a controlled environment to induce skin hardening.
View Article and Find Full Text PDFPhyto-cosmeceutical gel containing curcumin and quercetin loaded mixed micelles for improved anti-oxidant and photoprotective activity.
Colloids Surf B Biointerfaces
May 2024
Department of Quality Assurance, AISSMS College of Pharmacy, Kennedy Road, Near RTO, Pune, Maharashtra 411001, India.
Article Synopsis
- Ultra Violet (UV) radiation can cause various skin issues, including aging, cancer, and other disorders, highlighting the importance of effective sunscreen solutions.
- The study developed a novel phyto-dermal gel (PDG) that combines sun protection and antioxidant properties using polymeric mixed micelles loaded with curcumin and quercetin, showing promising results in SPF and antioxidant activity.
- Optimized PDG demonstrated good stability and safety on Wistar rats, indicating its potential for enhanced skin protection and therapeutic effects against UV-induced damage.
'Omalizumab changed my life': a patient perspective on solar urticaria.
Clin Exp Dermatol
July 2024
Photobiology Unit, Department of Dermatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Greater Manchester, UK.
Solar Urticaria and Omalizumab: A Retrospective Case-Control Study and Follow-Up.
Actas Dermosifiliogr
October 2024
Dermatology Department, Hospital General Universitario de Valencia, Spain.
Solar urticaria: clinical characteristics, treatment effectiveness, long-term prognosis, and QOL status in 29 patients.
Front Med (Lausanne)
February 2024
Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.
Article Synopsis
- Solar urticaria (SU) is a rare skin condition characterized by sensitivity to sunlight, often resistant to standard treatments, and its impact on patients' quality of life (QOL) has not been thoroughly studied.
- In a study of 29 Japanese SU patients, H1 antihistamines were effective for 75.8% of individuals, while UVA hardening therapy showed an 88.9% success rate, indicating some therapies can help improve symptoms.
- Overall, 90% of surveyed patients reported improvements since the onset of SU, with a mean Dermatology Life Quality Index score of 7.4, suggesting that while patients experience challenges, many see improvements over time.
Type I hypersensitivity in photoallergic contact dermatitis.
JAAD Case Rep
February 2024
Department of Dermatology, Weill Cornell Medical College, New York, New York.
Solar Urticaria: An Ambispective Study in a Long-term Follow-up Cohort with Emphasis on Therapeutic Predictors and Outcomes.
Acta Derm Venereol
January 2024
DDepartment of Dermatology, Hospital del Mar Research Institute. Universitat Pompeu Fabra, Barcelona, Spain.
Article Synopsis
- Solar urticaria is a rare skin condition triggered by sunlight, affecting 41 patients in a study that analyzed long-term outcomes and treatment approaches, particularly with omalizumab over 16 years.
- The study found that treating patients with omalizumab resulted in significant improvements in symptoms, as indicated by decreased levels of the high-affinity IgE receptor (FcεRI) and enhanced Urticaria Control Test scores.
- Despite a high drug survival rate of 88.9% at 48 months, only one patient successfully discontinued omalizumab on a stepping-down protocol, suggesting that ongoing monitoring and treatment may be necessary for most patients.
Solar urticaria involves rapid mast cell STAT3 activation and neutrophil recruitment, with FcεRI as an upstream regulator.
J Allergy Clin Immunol
May 2024
Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Greater Manchester, United Kingdom.
Article Synopsis
- Solar urticaria is a rare skin condition where sunlight triggers rapid hives, but its underlying mechanisms remain unclear.* -
- A study examined skin samples from patients with solar urticaria and healthy controls after UV radiation exposure, revealing increased activity of immune pathways, particularly involving neutrophils and pro-inflammatory molecules.* -
- Results indicate that mast cell activation and specific immune responses are essential in the development of solar urticaria, with potential similarities to chronic spontaneous urticaria, highlighting unique biomarkers for the condition.*
Chronic Urticaria and Angioedema: Masqueraders and Misdiagnoses.
J Allergy Clin Immunol Pract
August 2023
Department of Dermatology, Mayo Clinic, Rochester, Minn. Electronic address:
Article Synopsis
- Chronic urticaria is an itchy skin condition that lasts for at least 6 weeks, with both spontaneous cases (no clear triggers) and inducible cases (specific triggers like heat or cold).
- Angioedema is another condition that involves swelling beneath the skin, often occurring alongside chronic urticaria, but it lasts longer and can have different causes.
- Accurate diagnosis is crucial since chronic urticaria and angioedema can be confused with other conditions, impacting treatment and outcomes for patients.
Treatment of refractory solar urticaria: could dupilumab fill the current gap?
J Dtsch Dermatol Ges
June 2023
Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.
Physical urticaria: Clinical features, pathogenesis, diagnostic work-up, and management.
J Am Acad Dermatol
August 2023
St. John's Institute of Dermatology, Guy's Hospital, London, England.
Article Synopsis
- * Symptoms can vary and may include localized skin reactions, mucosal involvement, and systemic issues like nausea or headaches, potentially leading to severe reactions like anaphylaxis.
- * Accurate diagnosis of physical urticaria requires detailed clinical assessment and testing, which are essential for effective treatment and management strategies.
Systematic review of the clinical characteristics and natural history of solar urticaria.
J Am Acad Dermatol
July 2023
St. John's Institute of Dermatology, Guy's Hospital, London, UK.
Successful ligelizumab treatment of severe refractory solar urticaria.
J Allergy Clin Immunol Pract
August 2023
Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address:
Cover Image: Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
Br J Dermatol
April 2023
Department of Allergy, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Childhood fixed solar urticaria induced by visible light.
Photodermatol Photoimmunol Photomed
March 2023
Department of Dermatology, Kansai Medical University, Osaka, Japan.